title: Severe action tremor related to interferon-alpha 2b therapy for malignant melanoma.
abstract: Interferon (IFN)-alpha 2b is used for adjuvant therapy in malignant melanoma. Neurotoxicity as a side effect has been well described. Resting and action tremor related to interferon have been reported but are relatively uncommon. We report a case of a delayed-onset interferon-related action tremor in a patient with malignant melanoma.
authors.affiliation: Department of Medicine, Beth Israel Medical Center, New York, NY, USA. taiganishihori@yahoo.co.jp
authors.forename: Taiga
authors.initials: T
authors.lastname: Nishihori
authors.forename: May
authors.initials: M
authors.lastname: Abdo-Matkiwsky
authors.forename: Stewart B
authors.initials: SB
authors.lastname: Fleishman
authors.forename: Ronald H
authors.initials: RH
authors.lastname: Blum
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008545:Melanoma / Q000188:drug therapy*; D011994:Recombinant Proteins; D012720:Severity of Illness Index; D012878:Skin Neoplasms / Q000188:drug therapy*; D014202:Tremor / Q000139:chemically induced*
chemical_list: D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins